$ORGO

Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d117484dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 ORGANOGENESIS HOLDINGS INC. UP TO $75,000,000 OF CLASS A COMMON STOCK (par value $0.0001 per share) AT-THE-MARKET SALES AGREEMENT August 6, 2026 BTIG, LLC 65 East 55th Street New York, NY 10022 Citizens JMP Securities, LLC 1301

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 orgo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovat

Organogenesis Holdings Inc. (Nasdaq: ORGO) said it will release second-quarter fiscal 2026 financial results after market close on Aug. 6, 2026. The company will hold a conference call at 5:00 p.m. ET the same day to discuss results and provide a corporate update with Q&A. The webcast will be available on its investor site.

Organogenesis Holdings (ORGO) said the FDA accepted its BLA for ReNu, a cryopreserved amniotic suspension allograft for pain in symptomatic knee osteoarthritis. The company cited 3 randomized trials with 1,300+ patients and prior RMAT designation (2021). FDA set a PDUFA action date of April 24, 2027; “Amnuvx” is conditionally accepted as the proprietary name.

Organogenesis Holdings (Nasdaq: ORGO) said the FDA accepted for review its Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis pain. The FDA set a PDUFA target action date of April 24, 2027. The company noted ReNu has RMAT designation and was studied in three RCTs (>1,300 patients).

Organogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001661181 0001661181 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Ju

Organogenesis Holdings Inc. announced the extension of lease agreements for two facilities in Canton, Massachusetts, through December 31, 2032, with an option for renewal until 2034. These facilities are crucial for the company's manufacturing, operations, and research and development activities. The lease amendments were approved by the Audit Committee, considering that some major stockholders indirectly own the properties.

CANTON, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Organogenesis Holdings Inc. ( NASDAQ:ORGO ) , a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, ...

With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes ...